Aquestive Therapeutics Debt 2025

Aquestive Therapeutics Aktienanalyse

What does Aquestive Therapeutics do?

Aquestive Therapeutics Inc is a biopharmaceutical company based in Warren, New Jersey. The company specializes in the development of drugs for neurological disorders, rare diseases, and other medical needs. It was founded in 2004 and went public in 2018. The company operates in two main business segments: the development of proprietary drugs and the development of film technology for drug delivery. Both segments are closely connected and aim to provide innovative solutions for urgent medical needs. Aquestive's first business segment is the development of proprietary drugs for neurological disorders such as epilepsy, Parkinson's disease, and migraines. The company has various drug candidates in the pipeline, including a film-based sublingual tablet for the treatment of epilepsy and an injection solution for Parkinson's. These drug candidates are designed to complement or improve existing treatment options and achieve higher efficacy and tolerability for patients. Aquestive's second business segment is the development of film technology for drug delivery. Aquestive's patented film technology enables fast and reliable drug administration and can help improve the treatment of many diseases. Aquestive's film technology is particularly designed for drug administration through the mucous membranes of the mouth and throat. This includes film formulations for sublingual, buccal, or oromucosal drug delivery. An example of an Aquestive product is the sublingual film formulation of diazepam, marketed under the trade name Sympazan. Sympazan is approved for the treatment of LGS (Lennox-Gastaut syndrome), a rare and severe form of epilepsy. The sublingual film formulation of diazepam provides rapid onset of action and increased tolerability for patients compared to traditional dosage forms such as tablets or capsules. Aquestive has also specialized in the development of generic drugs for mucous membrane administration. The company produces sublingual, buccal, and oromucosal film formulations for a variety of medications, including drugs for pain, allergies, and nausea. Aquestive's generic drugs offer higher efficacy and tolerability for patients compared to conventional dosage forms such as tablets or capsules. Overall, Aquestive is an innovative company dedicated to improving patients' lives through novel therapeutic approaches. The company specializes in the development of film technology for drug delivery, providing a variety of innovative solutions for urgent medical needs. With its proprietary drug candidates and expertise in film technology, Aquestive is well-positioned to continue offering groundbreaking solutions for medical care. Aquestive Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Aquestive Therapeutics's Debt Structure

Aquestive Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Aquestive Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Aquestive Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Aquestive Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Aquestive Therapeutics stock

What is the debt of Aquestive Therapeutics this year?

Aquestive Therapeutics has a debt level of -39.02 USD this year.

What was the debt of Aquestive Therapeutics compared to the previous year?

The debt of Aquestive Therapeutics has increased by -1,166.7% compared to the previous year dropped.

What are the consequences of high debt for investors in Aquestive Therapeutics?

High debt can pose a risk for investors of Aquestive Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Aquestive Therapeutics?

Low debt means that Aquestive Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Aquestive Therapeutics affect the company?

An increase in debt of Aquestive Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Aquestive Therapeutics affect the company?

A reduction in debt of Aquestive Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Aquestive Therapeutics?

Some factors that can influence the debt of Aquestive Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Aquestive Therapeutics so important for investors?

The debts of Aquestive Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Aquestive Therapeutics take to change the debt?

To change the debt, Aquestive Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Aquestive Therapeutics pay?

Over the past 12 months, Aquestive Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aquestive Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Aquestive Therapeutics?

The current dividend yield of Aquestive Therapeutics is .

When does Aquestive Therapeutics pay dividends?

Aquestive Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aquestive Therapeutics?

Aquestive Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Aquestive Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aquestive Therapeutics located?

Aquestive Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aquestive Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aquestive Therapeutics from 7/12/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/12/2025.

When did Aquestive Therapeutics pay the last dividend?

The last dividend was paid out on 7/12/2025.

What was the dividend of Aquestive Therapeutics in the year 2024?

In the year 2024, Aquestive Therapeutics distributed 0 USD as dividends.

In which currency does Aquestive Therapeutics pay out the dividend?

The dividends of Aquestive Therapeutics are distributed in USD.